Evidence map›Paper›PMID 32791030›Full record

ArticleCancer biology & therapy2020

Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT.

Whitney F Handy, Keith T Schmidt, Douglas K Price, William D Figg

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Whitney F HandyBernard J. Dunn School of Pharmacy, Shenandoah University , Fairfax, VA, USA.
Keith T SchmidtClinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD, USA.
Douglas K PriceGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD, USA.
William D FiggClinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD, USA.
Center for Cancer Research · USNational Cancer Institute · USNational Institutes of Health · USShenandoah University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Chemohormonal Therapy vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) was a randomized phase III trial that evaluated the outcomes of men with metastatic prostate cancer who received castration with or without docetaxel. Patients from this trial were genotyped in a recent study to detect HSD3B1 variance and to determine 2-y freedom from castration-resistant prostate cancer as well as overall survival. The results of this study identified HSD3B1 as a possible biomarker that can be used to predict response to therapy in patients with metastatic disease.

Indexed as

Androgen AntagonistsProstatic NeoplasmsBiomarkersCastrationGenotypeHumansMaleMultienzyme ComplexesTreatment OutcomeAndrogen AntagonistsBiomarkersMultienzyme ComplexesADTCRPCdocetaxelgermline mutationsHSD3B1

Identifiers

PMID32791030
PMCPMC7515525
OpenAlexW3048785405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.